Detalles de la búsqueda
1.
Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
Europace
; 24(9): 1404-1411, 2022 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35512229
2.
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
Europace
; 23(1): 65-72, 2021 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33249467
3.
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Eur Heart J
; 41(47): 4497-4504, 2020 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32860041
4.
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet
; 394(10206): 1335-1343, 2019 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31492505
5.
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Eur Heart J
; 40(36): 3013-3021, 2019 09 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30976787
6.
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
BMC Cardiovasc Disord
; 19(1): 165, 2019 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31299906
7.
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Am Heart J
; 196: 105-112, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29421002
8.
Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
J Clin Med
; 10(4)2021 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33546442
9.
Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis.
Clin Res Cardiol
; 110(6): 831-840, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098470
10.
Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
J Chin Med Assoc
; 84(5): 485-490, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742992
11.
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
Eur Heart J Cardiovasc Pharmacother
; 7(FI1): f30-f39, 2021 04 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32790837
12.
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Eur J Intern Med
; 82: 48-55, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32826158
13.
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Thromb Res
; 196: 297-304, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32950897
14.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
J Cardiovasc Med (Hagerstown)
; 20(2): 97-104, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30540648
15.
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
Clin Cardiol
; 42(12): 1147-1154, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31650560
16.
Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients.
J Clin Hypertens (Greenwich)
; 20(2): 356-365, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462508
17.
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.
J Clin Hypertens (Greenwich)
; 19(12): 1309-1318, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29067756
18.
Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data.
Am J Cardiovasc Drugs
; 16(6): 427-437, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27565974
19.
Selecting methodologies for the evaluation of differences in time to response between antidepressants.
J Clin Psychiatry
; 63(8): 694-9, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12197449
20.
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.
Heart
; 100(20): 1625-35, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25106421